-
公开(公告)号：WO2015011120A3
公开(公告)日：2015-04-16
申请号：PCT/EP2014065675
申请日：2014-07-22
Applicant: BASF SE
Inventor： HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/506
CPC classification number: C07D417/12 , C07B2200/13 , C07D275/06
Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
Abstract translation: 本发明主要涉及分子结晶物质，优选结晶形式的达沙替尼盐，其包含式1化合物，优选式1化合物的阳离子和选自戊二酸，烟酸 和糖精，优选其阴离子。 本发明还涉及包含这种物质的药物组合物。 此外，本发明涉及制备所述物质的方法。 本发明还涉及使用所述物质或药物组合物治疗疾病的若干方面。
-
2.发明申请MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS 审中-公开包含DASATINIB和选择的晶体形成的多组分晶体
公开(公告)号：WO2013186726A3
公开(公告)日：2014-02-20
申请号：PCT/IB2013054832
申请日：2013-06-13
Applicant: BASF SE , BASF SCHWEIZ AG , BASF CHINA CO LTD
Inventor： CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , SIEBENHAAR BERND , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/506 , A61P35/00
CPC classification number: C07D417/12 , A61K31/506 , C07B2200/07 , C07B2200/13 , C07C35/12 , C07C47/58 , C07C65/03 , C07C69/84 , C07D213/82 , C07D309/40 , A61K2300/00
Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (lR,2S,5R)-(-)- menthol.
Abstract translation: 提供多组分结晶体（共晶体）及其用途，以及获得该组合物的方法。 所述多组分晶体系统（共晶体）包含达沙替尼和选自甲基 - 羟基苯甲酸甲酯，烟酰胺，没食子酸乙酯，没食子酸甲酯，没食子酸丙酯，乙基麦芽酚，香草醛，薄荷醇或（1R，2S，5R） - （ - ） - 薄荷脑
-
公开(公告)号：WO2015011119A2
公开(公告)日：2015-01-29
申请号：PCT/EP2014065674
申请日：2014-07-22
Applicant: BASF SE
Inventor： HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D417/12
CPC classification number: C07D417/12 , C07C55/12 , C07D213/80 , C07D275/06
Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
Abstract translation: 本发明主要涉及达沙替尼的盐，其中盐为无定形形式。 本文所述的盐优选包含式1化合物的阳离子和选自戊二酸，烟酸和糖精的第二化合物的阴离子。 本发明还涉及包含这种盐的药物组合物。 此外，本发明涉及制备所述盐的方法。 本发明还涉及使用所述盐或药物组合物治疗疾病的几个方面。
-
4.发明申请HYDROPHOBINS AS SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS 审中-公开作为表面活性蛋白的水解物作为固体药物制剂中的主要成分
公开(公告)号：WO2010060811A3
公开(公告)日：2010-10-21
申请号：PCT/EP2009065100
申请日：2009-11-13
Applicant: BASF SE , BUTHE ANDREAS , HAFNER ANDREAS , KAUFMANN FRANZ , GABOR ESTHER , MEURER GUIDO , ECK JUERGEN , BRADLEY GORDON
Inventor： BUTHE ANDREAS , HAFNER ANDREAS , KAUFMANN FRANZ , GABOR ESTHER , MEURER GUIDO , ECK JUERGEN , BRADLEY GORDON
CPC classification number: A61K9/4891 , A61K9/0065 , A61K9/2063 , A61K9/2095 , A61K9/2873 , C07K14/37
Abstract: The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e. g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.
Abstract translation: 本发明涉及用于制药技术中的表面活性疏水蛋白的用途，特别是作为涂覆液使用的赋形剂。 提供了将疏水蛋白与盖仑组合物混合或用含疏水蛋白的溶液处理药物形式的表面以改变盖仑膜形式的药物性质的方法。 在本发明的优选实施方案中，疏水蛋白用于改善药物组合物的性质，例如， G。 作为表面活性剂或增加耐受霜冻形式的崩解以实现延缓药物释放。 通过使用表面活性蛋白质作为赋形剂来修饰的盖仑形式可以是胶囊，片剂，丸剂，微粒，囊泡和栓剂，尽管可以预见到更多的盖仑制剂形式。 用于本发明目的的表面活性蛋白质可以从它们各自的天然来源中分离或者通过重组技术制备并在合适的宿主中表达。
-
公开(公告)号：EP2788344A4
公开(公告)日：2015-06-24
申请号：EP12855925
申请日：2012-12-03
Applicant: BASF SE
Inventor： HAFNER ANDREAS , HINTERMANN TOBIAS , BLATTER FRITZ , RODEL EVA
IPC: A61K31/506 , A61P31/10 , C07D403/06
CPC classification number: A61K31/506 , A61K31/194 , C07D403/10 , A61K2300/00
-
Patent Agency Ranking
公开(公告)号：EP3237941A4
公开(公告)日：2018-07-04
申请号：EP15872065
申请日：2015-12-18
Applicant: BASF SE
Inventor： STALDER MARTIN , GALLINET BENJAMIN , LUETOLF FABIAN , BASSET GUILLAUME , FERRINI ROLANDO , BUJARD PATRICE , VON MUEHLENEN ADRIAN , HAFNER ANDREAS
IPC: C09D5/00
CPC classification number: G02B5/282 , C23C14/0629 , C23C14/20 , C23C14/5873 , E06B9/24 , E06B2009/2417 , G02B1/118 , G02B5/281 , H01L31/02168
Abstract: A translucent or transparent film or sheet device shows angular-independent IR reflectance, which comprises a substrate (1) covered with a layer of a dielectric high refractive index material (4) containing a thin metallic layer (3) embedded in said material, and a further layer (5) of translucent or transparent material covering said layer (4) of dielectric high refractive index material, characterized in that the embedded metal layer (3) is periodically interrupted with a periodicity of 50 to 800 nm such that metal covers at least 70% of the substrate area. The device may advantageously be integrated into a window, a glass facade element or especially onto a photovoltaic (PV) device, where it reduces the fraction of IR radiation passing into the building, or reduces heat take-up and thus lowers the operating temperature and improves the efficiency of the PV cell.
-
7.发明公开
公开(公告)号：EP2861589A4
公开(公告)日：2016-03-02
申请号：EP13804937
申请日：2013-06-13
Applicant: BASF SE
Inventor： CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , SIEBENHAAR BERND , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/506 , A61P35/02
CPC classification number: C07D417/12 , A61K31/506 , C07B2200/07 , C07B2200/13 , C07C35/12 , C07C47/58 , C07C65/03 , C07C69/84 , C07D213/82 , C07D309/40 , A61K2300/00
-
公开(公告)号：AU2014292323B2
公开(公告)日：2018-08-30
申请号：AU2014292323
申请日：2014-07-08
Applicant: BASF SE
Inventor： HAFNER ANDREAS , VON MUHLENEN ADRIAN , ENGER OLIVIER , GALLINET BENJAMIN , FERRINI ROLANDO , MARJANOVIC NENAD , STALDER MARTIN , BASSET GUILLAUME , LUETOLF FABIAN
Abstract: A translucent construction element comprising a layer of translucent substrate, which contains a surface structured with nanoplanes of inclined angle relative to the substrate plane, and coated with an interrupted metallic layer covering at least a part of said nanoplanes, is characterized by a high density of interruptions in the metallic layer of low thickness; the periodicity of interruptions in the metallic layer generally is from the range 50 to 1000 nm and the thickness of the metallic layer typically is from the range 1 to 50 nm. The construction element may be integrated, for example, into windows, plastic films or sheets or glazings, especially for the purpose of light management.
-
公开(公告)号：AU2013333953A1
公开(公告)日：2015-04-30
申请号：AU2013333953
申请日：2013-10-16
Applicant: BASF SE
Inventor： CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , RODEL EVA , VOSSEN MARCUS
IPC: C07D401/14 , A61K31/506 , A61P35/02
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
-
公开(公告)号：CA2887540A1
公开(公告)日：2014-04-24
申请号：CA2887540
申请日：2013-10-16
Applicant: BASF SE
Inventor： CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SZELAGIEWICZ MARTIN , BLATTER FRITZ , RODEL EVA , VOSSEN MARCUS
IPC: C07D401/14 , A61K31/506 , A61P35/02
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
-
-
-
-
-
-
-
-
-
Search Results
44
records
(took 0.021 seconds)
